Mo
Morphosys (Novartis)
Munich DEFounded 1992600 employees
Private CapbiotechAcquiredOncologyHematology
Platform: Pelabresib
Market Cap
N/A
All Drugs
2
Clinical Trials
2
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| MOR-3925 | MOR-3925 | Phase 1/2 | 1 | PLK4 | Myelofibrosis | ||
| MOR-6182 | MOR-6182 | Phase 1/2 | 1 | TNFα | HSThymoma |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (2)